In The News Posted September 11, 2023 Share Posted September 11, 2023 IRVINE, Kalifornien, 11. September 2023 /PRNewswire/ -- PeproMene Bio, Inc., ein im klinischen Stadium tätiges Biotech-Unternehmen, das neuartige Therapien zur Behandlung von Krebs- und Immunkrankheiten entwickelt, gab heute bekannt, dass die erste Dosis-Kohorte seiner klinischen...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now